Investment Overview >$8bn. | Leverage ratio stable with 2023 year-end | --- | --- | --- | --- | --- | |---------------------------|----------|----------|----------|----------| | $ mil | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | | Cash and cash equivalents | 737 | 706 | 693 | 575 | | Gross Debt (1) | 9,134 | 8,913 | 8,760 | 8,714 | | Net Debt (1) | 8,397 | 8,207 | 8,067 | 8,139 | Furthermore, Organon's Established Brands division consists of >50 drugs whose patents are expiring, or have long since expired, ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Therefore, the Zacks rating upgrade for Organon basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in a company's future earnings potential, as reflected in earnings e ...

The pharmaceutical company's shares have seen an increase of 1.87% over the last month, surpassing the Medical sector's gain of 0.71% and falling behind the S&P 500's gain of 3.82%. Investors should also note any recent changes to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. The Zacks Rank system, running from #1 (Strong Buy) to #5 (St ...

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Organon possesses a Zacks Rank of #3 (Hold). Organon (OGN) ended the recent trading session at $19.93, demonstrating a -1.04% swing from the preceding day's closing price. This change lagged the S&P 500's 0.07% gain o ...

In the latest market close, Organon (OGN) reached $20.63, with a -0.77% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.16%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.49%. Prior to today's trading, shares of the pharmaceutical company had lost 0.91% over the past month. This has lagged the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. The upcoming earnings rel ...

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as w ...

Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. The pharmaceutical company's shares have seen a decrease of 7.33% over the last month, not keeping up with the Medical sector's gain of 0.03% and the S&P 500's gain of 3.59%. OGN's full-year Z ...

Last Reported Results and Surprise History Over the past month, shares of this pharmaceutical company have returned -5.1%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 0.9%. The key question now is: What could be the stock's future direction? Revisions to Earnings Estimates We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the la ...

OGN has rallied 8.8% over the past four weeks, and the company is a Zacks Rank #1 (Strong Buy) at the moment. This combination suggests OGN could be on the verge of another move higher. The bullish case solidifies once investors consider OGN's positive earnings estimate revisions. No estimate has gone lower in the past two months for the current fiscal year, compared to 3 higher, while the consensus estimate has increased too. With a winning combination of earnings estimate revisions and hitting a key techn ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned +9.2% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has lost 2.8% over this period. Now the key question is: Where could the stock be headed in the near term? Although media repo ...